amikacin

Summary

Summary: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.

Top Publications

  1. ncbi Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections
    P Meers
    Transave, Inc, 11 Deer Park Dr, Suite 117, Monmouth Junction, NJ 08852, USA
    J Antimicrob Chemother 61:859-68. 2008
  2. pmc Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review
    Sophia B Georghiou
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS ONE 7:e33275. 2012
  3. ncbi Thiolated chitosan nanoparticles as an oral delivery system for Amikacin: in vitro and ex vivo evaluations
    F Atyabi
    Novel Drug Delivery Systems Lab, Faculty of Pharmacy, Medical Sciences University of Tehran, Tehran 14155 6451, Iran
    J Nanosci Nanotechnol 9:4593-603. 2009
  4. pmc High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene
    Levan Jugheli
    Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium
    Antimicrob Agents Chemother 53:5064-8. 2009
  5. pmc Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis
    Annika Kruuner
    Department of Bacteriology, Swedish Institute for Infectious Disease Contro, Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden
    Antimicrob Agents Chemother 47:2971-3. 2003
  6. pmc Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis
    M Analise Zaunbrecher
    Microbiology and Molecular Genetics Graduate Program, Department of Microbiology and Immunology, Rollins Research Center, Emory University, Atlanta, GA 30322, USA
    Proc Natl Acad Sci U S A 106:20004-9. 2009
  7. ncbi Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis
    Anna Engström
    Swedish Institute for Infectious Disease Control SMI, Solna, Sweden
    J Antimicrob Chemother 66:1247-54. 2011
  8. ncbi Adaptive resistance to benzalkonium chloride, amikacin and tobramycin: the effect on susceptibility to other antimicrobials
    J A Joynson
    Kings College London, Sharnbrook, Bedfordshire, UK
    J Appl Microbiol 93:96-107. 2002
  9. pmc Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis
    Courtney E Maus
    Centers for Disease Control and Prevention, Mailstop G35, 1600 Clifton Road, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 49:3192-7. 2005
  10. pmc In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans
    Baohong Ji
    Bactériologie Hygiène, Faculte de Medecine Pierre et Marie Curie, Universite Paris 6, France
    Antimicrob Agents Chemother 50:1921-6. 2006

Detail Information

Publications288 found, 100 shown here

  1. ncbi Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections
    P Meers
    Transave, Inc, 11 Deer Park Dr, Suite 117, Monmouth Junction, NJ 08852, USA
    J Antimicrob Chemother 61:859-68. 2008
    ..We have investigated the biofilm penetration, mechanism of drug release and in vivo antimicrobial activity of a unique nanoscale liposomal formulation of amikacin designed specifically for nebulization and inhaled delivery.
  2. pmc Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review
    Sophia B Georghiou
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS ONE 7:e33275. 2012
    ..this relationship is well established and reliable for first-line anti-TB drugs, rifampin and isoniazid, it is less well-studied and understood for second-line, injectable drugs, amikacin (AMK), kanamycin (KAN) and capreomycin (CAP).
  3. ncbi Thiolated chitosan nanoparticles as an oral delivery system for Amikacin: in vitro and ex vivo evaluations
    F Atyabi
    Novel Drug Delivery Systems Lab, Faculty of Pharmacy, Medical Sciences University of Tehran, Tehran 14155 6451, Iran
    J Nanosci Nanotechnol 9:4593-603. 2009
    ..TPP gelation yields smaller, more spherical shaped nanoparticles with a smaller range of size distribution. Amikacin loaded nanoparticles with an average size of 280 nm were prepared by TPP gelation in which disulfide bond ..
  4. pmc High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene
    Levan Jugheli
    Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium
    Antimicrob Agents Chemother 53:5064-8. 2009
    The aminoglycosides kanamycin and amikacin and the macrocyclic peptide capreomycin are key drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB)...
  5. pmc Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis
    Annika Kruuner
    Department of Bacteriology, Swedish Institute for Infectious Disease Contro, Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden
    Antimicrob Agents Chemother 47:2971-3. 2003
    ..that there is full cross-resistance in Mycobacterium tuberculosis between the aminoglycoside drugs kanamycin and amikacin. However, kanamycin resistance and amikacin susceptibility were seen in 43 of 79 (54%) multidrug-resistant ..
  6. pmc Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis
    M Analise Zaunbrecher
    Microbiology and Molecular Genetics Graduate Program, Department of Microbiology and Immunology, Rollins Research Center, Emory University, Atlanta, GA 30322, USA
    Proc Natl Acad Sci U S A 106:20004-9. 2009
    ..The aminoglycosides kanamycin and amikacin are important bactericidal drugs used to treat MDR TB, and resistance to one or both of these drugs is a defining ..
  7. ncbi Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis
    Anna Engström
    Swedish Institute for Infectious Disease Control SMI, Solna, Sweden
    J Antimicrob Chemother 66:1247-54. 2011
    ..cross-resistance and drug-resistance mechanisms for the cyclic peptide capreomycin and the aminoglycosides amikacin and kanamycin by comparing genotypes and phenotypes of clinical isolates and in vitro selected mutants of ..
  8. ncbi Adaptive resistance to benzalkonium chloride, amikacin and tobramycin: the effect on susceptibility to other antimicrobials
    J A Joynson
    Kings College London, Sharnbrook, Bedfordshire, UK
    J Appl Microbiol 93:96-107. 2002
    To produce strains of antimicrobial-resistant Pseudomonas aeruginosa via adaptation to benzalkonium chloride, amikacin and tobramycin and to then examine the incidence, or otherwise, of cross-resistance between antibiotics and between ..
  9. pmc Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis
    Courtney E Maus
    Centers for Disease Control and Prevention, Mailstop G35, 1600 Clifton Road, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 49:3192-7. 2005
    Capreomycin, kanamycin, amikacin, and viomycin are drugs that are used to treat multidrug-resistant tuberculosis. Each inhibits translation, and cross-resistance to them is a concern during therapy...
  10. pmc In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans
    Baohong Ji
    Bactériologie Hygiène, Faculte de Medecine Pierre et Marie Curie, Universite Paris 6, France
    Antimicrob Agents Chemother 50:1921-6. 2006
    ..demonstrated the lowest MIC(50) and MIC(90), followed by moxifloxacin (MXF), streptomycin (STR), rifampin (RIF), amikacin (AMK), linezolid (LZD), and PA-824...
  11. ncbi A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function
    Waleed M Sweileh
    Clinical Pharmacology, An Najah National University, Nablus, Palestine
    Fundam Clin Pharmacol 23:515-20. 2009
    The aim of this study was to compare the nephrotoxic potential of amikacin (AK) and gentamicin (GM) in patients with normal baseline renal function...
  12. ncbi Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada ca
    Expert Rev Anti Infect Ther 10:459-73. 2012
    ....
  13. ncbi Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains
    Dorota Wojnicz
    Department of Biology and Medical Parasitology, Medical University of Wroclaw, Mikulicza Radeckiego 9, 50 367 Wroclaw, Poland
    Int J Antimicrob Agents 29:700-4. 2007
    The effect of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to uroepithelial cells of Escherichia coli strains was investigated...
  14. ncbi Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa
    Qin Lu
    Multidisciplinary Intensive Care Unit Pierre Viars, Department of Anesthesiology and Critical Care Medicine, La Pitie Salpetriere Hospital, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    Am J Respir Crit Care Med 184:106-15. 2011
    ..In experimental pneumonia, nebulization of antibiotics provides high lung tissue concentrations and rapid bacterial killing...
  15. pmc Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex
    S Y Grace Lin
    Microbial Diseases Laboratory, CDPH, 850 Marina Bay Parkway, Richmond, CA 94804, USA
    J Clin Microbiol 47:3630-4. 2009
    ..The four drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide. The critical concentration established for levofloxacin and amikacin was 1...
  16. pmc Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis
    Patricia J Campbell
    Mycobacteriology Laboratory Branch, Division of Tuberculosis Elimination, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Bldg 17, Room 4029, M S F08, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 55:2032-41. 2011
    ..drugs isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB) and the second-line drugs amikacin (AMK), capreomycin (CAP), kanamycin (KAN), ciprofloxacin (CIP), and ofloxacin (OFX)...
  17. ncbi Occurrence and mechanisms of amikacin resistance and its association with beta-lactamases in Pseudomonas aeruginosa: a Korean nationwide study
    Ja Young Kim
    Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
    J Antimicrob Chemother 62:479-83. 2008
    We investigated the occurrence and mechanism of amikacin resistance and its association with various beta-lactamase genes in Pseudomonas aeruginosa isolates.
  18. pmc Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment
    Silke Feuerriegel
    Research Center Borstel, National Reference Center for Mycobacteria, Parkallee 18, 23845 Borstel, Germany
    Antimicrob Agents Chemother 53:3353-6. 2009
    ..we analyzed Mycobacterium tuberculosis strains resistant to ofloxacin (n = 26) and to capreomycin and/or amikacin (n = 48) from Uzbekistan for variations in target genes (gyrA, gyrB, rrs, and tlyA)...
  19. pmc Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis
    G J Alangaden
    Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 42:1295-7. 1998
    ..was identified in Mycobacterium tuberculosis (MTB) strain ATCC 35827 and in 13 MTB clinical isolates resistant to amikacin-kanamycin (MICs, >128 microg/ml)...
  20. pmc Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009
    Kyungwon Lee
    Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
    Yonsei Med J 52:793-802. 2011
    ..The aim of this study was to analyze antimicrobial resistance data generated in 2009 by hospitals and commercial laboratories participating in the Korean Nationwide Surveillance of Antimicrobial Resistance program...
  21. pmc Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice
    Herve Dega
    Faculté de Médecine Pitié Salpêtrière, Service de Bacteriologie et Hygiene, 75634 Paris Cedex 13, France
    Antimicrob Agents Chemother 46:3193-6. 2002
    ..five doses weekly of one of the following regimens: (i) 10 mg of RIF/kg alone; (ii) 10 mg of RIF/kg and 100 mg of amikacin (AMK)/kg; and (iii) 10 mg of RIF/kg, 100 mg of clarithromycin (CLR)/kg, and 50 mg of sparfloxacin (SPX)/kg...
  22. ncbi Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases
    Charles A Peloquin
    Division of Infectious Diseases, Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206, USA
    Clin Infect Dis 38:1538-44. 2004
    ..by drug to receive 15 mg/kg per day or 25 mg/kg 3 times per week of intravenous streptomycin, kanamycin, or amikacin. Doses were adjusted to achieve target serum concentrations...
  23. ncbi Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model
    Ming Du
    Department of Microbiology, The University of Alabama at Birmingham, 35294 2170, USA
    J Mol Med (Berl) 84:573-82. 2006
    ..To address this problem, we identified doses of both gentamicin and amikacin that resulted in peak serum levels within their accepted clinical ranges...
  24. pmc Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis
    Yan Feng
    Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, People s Republic of China
    PLoS ONE 8:e55292. 2013
    ..to synthesize the latest data on the diagnostic accuracy of GenoType MTBDRsl in detecting drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol, in comparison with the phenotypic drug susceptibility test.
  25. pmc Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria
    Rebecca Greendyke
    The University of New Mexico School of Medicine, Albuquerque, New Mexico 87131, USA
    Antimicrob Agents Chemother 52:2019-26. 2008
    ..b>Amikacin, cefoxitin, and clarithromycin are standard therapies for this infection...
  26. ncbi Modulation of melanogenesis and antioxidant defense system in melanocytes by amikacin
    Dorota Wrześniok
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Silesia, Jagiellonska 4, PL 41 200 Sosnowiec, Poland
    Toxicol In Vitro 27:1102-8. 2013
    b>Amikacin is principally used to treat infections caused by microorganisms resistant to other aminoglycosides...
  27. ncbi Ototoxicity and otoprotection in the inner ear of guinea pigs using gentamicin and amikacin: ultrastructural and functional aspects
    Thomaz José Marra de Aquino
    Departamento de Oftalmologia, Otorrinolaringologia e Cirurgia de Cabeca e Pescoco, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo
    Braz J Otorhinolaryngol 74:843-52. 2008
    ..The discovery of self-protecting endogenous mechanisms of the outer hair cells associated with their functional and ultra-structural assessment methods has opened new horizons in the understanding and controlling of these mechanisms...
  28. ncbi Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis
    Frederick A Sirgel
    DST NRF Centre of Excellence for Biomedical TB Research MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Health Science, Stellenbosch University, Cape Town, South Africa
    Microb Drug Resist 18:193-7. 2012
    The aminoglycosides amikacin (AMK)/kanamycin (KAN) and the cyclic polypeptide capreomycin (CAP) are important injectable drugs in the treatment of multidrug-resistant tuberculosis...
  29. ncbi Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates
    Deepak Batura
    Department of Urology, Northwick Park Hospital, London, UK
    BJU Int 107:760-4. 2011
    To examine the efficacy of adding amikacin to fluoroquinolone-based antimicrobial prophylaxis in preventing transrectal ultrasonography-guided prostate biopsy (TGB) associated infections.
  30. pmc Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain
    J Vila
    Department de Microbiologia, Institut d Investigacio Biomedica August Pi i Sunyer, Hospital Clinic, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain
    J Clin Microbiol 37:758-61. 1999
    Sixteen amikacin-resistant clinical Acinetobacter baumannii isolates from nine different hospitals in Spain were investigated to determine whether the high incidence of amikacin-resistant A...
  31. ncbi Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial
    F Alvarez-Lerma
    Intensive Care Unit, Hospital del Mar, Autonomous University of Barcelona, Passeig Marítim 25 29, 08003 Barcelona, Spain
    Intensive Care Med 27:493-502. 2001
    ..and bacteriological efficacy as well as tolerability of two regimens of broad-spectrum antibiotics (ceftazidime versus piperacillin/tazobactam) combined with amikacin in the treatment of nosocomial pneumonia in intensive care patients.
  32. ncbi Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection
    Oscar Cirioni
    Clinic of Infectious Diseases, Università Politecnica delle Marche Ospedali Riuniti, Ancona, Italy
    J Antimicrob Chemother 66:1318-23. 2011
    An experimental study was performed to evaluate both in vitro and in vivo the efficacy of clarithromycin coating combined with systemic amikacin in preventing ureteral stent biofilm infection due to Pseudomonas aeruginosa.
  33. ncbi Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa
    S Islam
    Division of Clinical Bacteriology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Clin Microbiol Infect 10:877-83. 2004
    ..b>Amikacin-resistant (AR) mutants were generated from P. aeruginosa strain PAO1, and clinical isolates of P...
  34. pmc Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii
    Tze Peng Lim
    Singapore General Hospital, Singapore, Singapore
    Antimicrob Agents Chemother 52:2898-904. 2008
    ..clinical isolate of Acinetobacter baumannii with escalating concentrations of cefepime (0 to 512 mg/liter), amikacin (0 to 256 mg/liter), and levofloxacin (0 to 64 mg/liter)...
  35. ncbi A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia
    A Del Favero
    Istituto Medicina Interna e Scienze Oncologiche, Università di Perugia, Perugia, Italy
    Clin Infect Dis 33:1295-301. 2001
    ..5 g 3 times daily intravenously) plus placebo versus piperacillin-tazobactam plus amikacin (7...
  36. ncbi Outbreak of Nocardia keratitis after photorefractive keratectomy: clinical, microbiological, histopathological, and confocal scan study
    Mohammad Ali Javadi
    Labbafinejad Ophthalmic Research Center, Shaheed Beheshti Medical University, Tehran, Iran
    J Cataract Refract Surg 35:393-8. 2009
    ..All eyes responded favorably to topical amikacin and the infection resolved without recurrence...
  37. ncbi A cluster of Nocardia keratitis after LASIK
    Prashant Garg
    Cornea and Anterior Segment Service, L V Prasad Eye Institute, Hyderabad, India
    J Refract Surg 23:309-12. 2007
    ..To report a cluster of Nocardia asteroides keratitis cases after LASIK...
  38. ncbi In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans
    H S Thangaraj
    Division of Infectious Diseases, St George s Hospital Medical School, London SW17 0RE, UK
    J Antimicrob Chemother 45:231-3. 2000
    MICs of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin were determined for 14 primary clinical isolates and three reference isolates of Mycobacterium ulcerans by modifying a standard agar dilution method for testing ..
  39. ncbi Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia
    A Chrispal
    Department of Medicine II, Christian Medical College, Vellore, India
    J Postgrad Med 55:208-10. 2009
    ..We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria...
  40. pmc Inhibition of aac(6')-Ib-mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria
    Alfonso J C Soler Bistué
    Fundacion Instituto Leloir, Instituto de Investigaciones Bioquímicas de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas and Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Patricias Argentinas 435, C1405BWE Buenos Aires, Argentina
    Proc Natl Acad Sci U S A 106:13230-5. 2009
    ..The rise in multiresistant bacteria harboring AAC(6')-Ib has seriously limited the effectiveness of amikacin and other aminoglycosides...
  41. ncbi In vitro studies of amikacin-loaded human carrier erythrocytes
    Carmen Gutiérrez Millán
    Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Salamanca, Spain
    Transl Res 152:59-66. 2008
    ..In this study, the encapsulation of amikacin by human carrier erythrocytes prepared using a hypo-osmotic dialysis was investigated...
  42. ncbi A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers
    Jeffry Weers
    Transave, Inc, Monmouth Junction, New Jersey, USA
    J Aerosol Med Pulm Drug Deliv 22:131-8. 2009
    The purpose of this study was to investigate the inhalation of a liposomal formulation of amikacin in healthy male volunteers in terms of pulmonary deposition, clearance, and safety following nebulization with a commercial jet nebulizer.
  43. pmc Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin
    Sébastien Lefrançois
    Laboratoire de Bacteriologie Hygiene, Faculte de Medecine Pierre et Marie Curie, Universite Paris 6, and CNRM et de la Résistance aux Antituberculeux, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hôpital de Paris, France
    Antimicrob Agents Chemother 51:645-50. 2007
    ..of various durations of treatment with a combination of rifampin (RIF) and either streptomycin (STR) or amikacin (AMK) in murine Mycobacterium ulcerans infection were compared in two experiments...
  44. ncbi Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy
    Fabio Silvio Taccone
    Department of Intensive Care, Erasme Hospital, Brussels, Belgium
    Int J Antimicrob Agents 37:531-5. 2011
    Data on the optimal amikacin regimen during continuous renal replacement therapy (CRRT) are scarce and the proposed loading dose of 10mg/kg may result in inadequate drug levels...
  45. pmc Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles
    Solmaz Ghaffari
    Department of Pharmaceutics, Faculty of Pharmacy and Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
    Int J Nanomedicine 6:35-43. 2011
    Solid lipid nanoparticles (SLNs) of amikacin were designed in this study for pulmonary delivery to reduce the dose or its administration intervals leading to reduction of its toxicities especially in long term treatment...
  46. pmc Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection
    Olanrewaju O Okusanya
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Inc, Albany, New York, USA
    Antimicrob Agents Chemother 53:3847-54. 2009
    The pharmacokinetics and pharmacodynamics of a novel liposomal amikacin for inhalation were evaluated in cystic fibrosis patients with chronic pseudomonas infection...
  47. ncbi Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, OH 45229 3039, USA
    Eur J Clin Pharmacol 65:705-13. 2009
    To examine the pharmacokinetics of amikacin and its pharmacokinetic pharmacodynamic (PKPD) relationship in neonates. To develop an alternative dosing strategy for amikacin in neonates.
  48. pmc Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin
    Marta Toth
    Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, USA
    Antimicrob Agents Chemother 54:1590-5. 2010
    ..generated R92H/D268N and N196D/D268N mutant enzymes, resulting in elevated levels of resistance to amikacin and isepamicin but not to other aminoglycoside antibiotics...
  49. ncbi Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size
    Zhili Li
    Transave, Inc, Monmouth Junction, New Jersey 08852, USA
    J Aerosol Med Pulm Drug Deliv 21:245-54. 2008
    ..g., central vs. peripheral). In this report, a liposomal amikacin formulation (Arikace, a registered trademark of Transave, Inc...
  50. pmc Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides
    Renee Sarno
    Department of Biological Science, College of Natural Science and Mathematics, California State University Fullerton, Fullerton, California 92834 6850, USA
    Antimicrob Agents Chemother 47:3296-304. 2003
    b>Amikacin has been very useful in the treatment of infections caused by multiresistant bacteria because it is refractory to the actions of most modifying enzymes...
  51. ncbi Antioxidant enzyme levels inversely covary with hearing loss after amikacin treatment
    James J Klemens
    Southern Illinois University School of Medicine, Springfield, IL, USA
    J Am Acad Audiol 14:134-43. 2003
    ..For 28 days, albino guinea pigs were administered either 200 mg/kg/day amikacin, or saline subcutaneously...
  52. ncbi Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina
    Muhammad Jamshaid
    Faculty of Pharmacy, University of the Punjab, Lahore, Pakistan
    Eur J Drug Metab Pharmacokinet 28:1-6. 2003
    Three commercially available brands of amikacin were investigated in a parallel study design for the assessment of comparative pharmacokinetics in pediatric oncology patients with chemotherapy-induced neutropenic febrile episode...
  53. ncbi In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa
    L Piccoli
    Medicines Research Center, GlaxoSmithKline, Via A Fleming 4, Verona 37135, Italy
    J Chemother 17:355-60. 2005
    ..explore the antibacterial activity of the levofloxacin (LVX) and ceftazidime (CAZ) combination compared with the amikacin (AMK)/CAZ combination against Pseudomonas aeruginosa...
  54. pmc Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin
    Zachary L Cox
    Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA
    Am J Health Syst Pharm 68:624-32. 2011
    The impact of clinical decision support (CDS) on initial doses and intervals and pharmacokinetic outcomes of amikacin and tobramycin therapy was evaluated.
  55. ncbi Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia
    M J Rodriguez-Hernandez
    Service of Infectious Diseases and Service of Microbiology, Hospital Universitario Virgen del Rocio, Avenida Manuel Siurot s n, 41013 Seville, Spain
    J Antimicrob Chemother 45:493-501. 2000
    ..This model was used to compare the efficacy of imipenem, doxycycline and amikacin in monotherapy, and the combination of imipenem plus amikacin and doxycycline plus amikacin...
  56. pmc n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa
    Evangelos J Giamarellos-Bourboulis
    4th Department of Internal Medicine, Medical School, University of Athens, Athens, Greece
    Antimicrob Agents Chemother 48:4713-7. 2004
    ..of gamma-linolenic acid (GLA) and arachidonic acid (AA) were administered intravenously with ceftazidime and amikacin in rabbits with sepsis caused by one multidrug-resistant isolate...
  57. ncbi Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China
    Qinglin Du
    Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco Environment and Bio Resource of the Three Gorges Area, Key Laboratory of Ministry of Education Eco Environment of the Three Gorges Reservoir Region, School of Life Sciences, Southwest University, Beibei, Chongqing 400715, China
    Diagn Microbiol Infect Dis 77:138-42. 2013
    ..resistance level with the injectable second-line anti-tuberculosis drugs (SLDs) including kanamycin (KAN), amikacin (AMK), and capreomycin (CAP) remain elusive...
  58. pmc External guide sequences targeting the aac(6')-Ib mRNA induce inhibition of amikacin resistance
    Alfonso J C Soler Bistué
    Department of Biological Science, College of Natural Science and Mathematics, California State University Fullerton, Fullerton, CA 92834 6850, USA
    Antimicrob Agents Chemother 51:1918-25. 2007
    The dissemination of AAC(6')-I-type acetyltransferases have rendered amikacin and other aminoglycosides all but useless in some parts of the world. Antisense technologies could be an alternative to extend the life of these antibiotics...
  59. ncbi Crystal structure of the bacterial ribosomal decoding site complexed with amikacin containing the gamma-amino-alpha-hydroxybutyryl (haba) group
    Jiro Kondo
    Institut de Biologie Moleculaire et Cellulaire, UPR9002 CNRS, Universite Louis Pasteur, 15, rue René Descartes, 67084 Strasbourg, France
    Biochimie 88:1027-31. 2006
    b>Amikacin is the 4,6-linked aminoglycoside modified at position N1 of the 2-deoxystreptamine ring (ring II) by the L-haba group...
  60. ncbi Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis
    A Safdar
    Anderson Cancer Center, Houston, TX, USA
    Eur J Clin Microbiol Infect Dis 31:1883-7. 2012
    ..Aerosolized amikacin (aeAmk) was given to nine patients who had failed standard combination oral antimycobacterial drugs...
  61. ncbi Interaction of neomycin, tobramycin and amikacin with melanin in vitro in relation to aminoglycosides-induced ototoxicity
    E Buszman
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Silesia, Sosnowiec, Poland
    Pharmazie 62:210-5. 2007
    ..The binding of neomycin, tobramycin and amikacin to model synthetic melanin was studied...
  62. ncbi The early bactericidal activity of amikacin in pulmonary tuberculosis
    P R Donald
    Department of Paediatrics, University of Stellenbosch, Cape Town, South Africa
    Int J Tuberc Lung Dis 5:533-8. 2001
    ..OBJECTIVE: To determine the early bactericidal activity (EBA) of amikacin in dosages of 5 mg/kg, 10 mg/kg and 15 mg/kg body weight in comparison to that of isoniazid 6 mg/kg body weight ..
  63. ncbi Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate
    Elijah O Kehinde
    Department of Surgery Division of Urology, Faculty of Medicine, Kuwait University, Kuwait
    J Urol 189:911-5. 2013
    ..2001 and 2005 when only oral ciprofloxacin was used prophylactically (group 1) to the incidence among patients undergoing biopsy between 2006 and 2010 when a single dose of intravenous amikacin was added to ciprofloxacin (group 2).
  64. pmc Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India
    Alka Khanna
    Department of Biotechnology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, India
    Antimicrob Agents Chemother 54:4789-93. 2010
    ..and sequencing the following genes: rpoB (rifampin), katG (isoniazid), gyrA (fluoroquinolones), and rrs (amikacin, kanamycin, and capreomycin)...
  65. ncbi Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan
    Chien Wen Huang
    Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Fong Yuan Hospital, Taiwan Department of Health, Taichung, Taiwan, ROC
    Int J Antimicrob Agents 41:218-23. 2013
    ..Clarithromycin and amikacin were tested alone as well as for synergistic effect with tigecycline...
  66. ncbi Cell wall thickening is associated with adaptive resistance to amikacin in methicillin-resistant Staphylococcus aureus clinical isolates
    Wenchang Yuan
    Department of Microbiology, College of Basic Medical Sciences, Third Military Medical University, Chongqing, China
    J Antimicrob Chemother 68:1089-96. 2013
    ..The mechanism of MRSA resistance to amikacin is poorly understood...
  67. pmc Appearance of amikacin and tobramycin resistance due to 4'-aminoglycoside nucleotidyltransferase [ANT(4')-II] in gram-negative pathogens
    G A Jacoby
    Massachusetts General Hospital, Boston 02114
    Antimicrob Agents Chemother 34:2381-6. 1990
    Following the use of amikacin as the principal aminoglycoside at a Denver hospital, amikacin resistance appeared first in Pseudomonas aeruginosa and then in Escherichia coli, Klebsiella pneumoniae, and other enteric organisms from ..
  68. ncbi BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia
    Michael S Niederman
    Department of Medicine, Winthrop University Hospital, 222 Station Plaza N, Suite 509, Mineola, NY 11501, USA
    Intensive Care Med 38:263-71. 2012
    ..double-blind, phase II study of BAY41-6551 (NCT01004445), an investigational drug-device combination of amikacin, formulated for inhalation, and a proprietary Pulmonary Drug Delivery System, for the treatment of Gram-negative ..
  69. ncbi The major aminoglycoside-modifying enzyme AAC(3)-II found in Escherichia coli determines a significant disparity in its resistance to gentamicin and amikacin in China
    Yonghong Xiao
    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
    Microb Drug Resist 18:42-6. 2012
    ..However, less than 15% of isolates were resistant to amikacin and isepamicin. Of the gentamicin-resistant strains, 88.2% and 86...
  70. pmc Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series
    Kala K Davis
    Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA, USA
    BMC Pulm Med 7:2. 2007
    ..The addition of aerosolized amikacin to standard oral therapy for nontuberculous mycobacterial pulmonary infection may improve treatment efficacy ..
  71. ncbi Amikacin-induced acute renal injury in rats: protective role of melatonin
    Hakan Parlakpinar
    Department of Pharmacology, Faculty of Medicine and Biology, Inonu University, Malatya, Turkey
    J Pineal Res 35:85-90. 2003
    ..pineal gland and a highly effective antioxidant and free radical scavenger, reduces the nephrotoxicity caused by amikacin (AK)...
  72. pmc Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration
    Kevin S Akers
    Infectious Disease Service, San Antonio Military Medical Center, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Antimicrob Agents Chemother 55:4639-42. 2011
    b>Amikacin clearance can be increased in burn injury, which is often complicated by renal insufficiency...
  73. ncbi Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial
    L Gómez
    Infectious Diseases Unit, Hospital Universitari Mutua de Terrassa, University of Barcelona, Terrassa, Barcelona, Spain
    Eur J Clin Microbiol Infect Dis 29:417-27. 2010
    ..We performed a prospective, randomized trial to evaluate the efficacy of low-dose cefepime plus amikacin (C-A) compared to low-dose piperacillin/tazobactam plus amikacin (PT-A)...
  74. pmc Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses
    Y Q Xiong
    St John s Cardiovascular Research Center, LAC UCLA Medical Center, Torrance, California 90509, USA
    Antimicrob Agents Chemother 43:1737-42. 1999
    ..aureus in vitro and in vivo. MiKasome, a new liposome-encapsulated formulation of conventional amikacin, significantly prolongs serum half-life (t1/2) and increases the area under the concentration-time curve (AUC) ..
  75. ncbi Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin
    Jesus Hermida
    Laboratorio Central, Hospital Clinico Universitario, 15706 Santiago de Compostela, Spain
    Ther Drug Monit 28:326-31. 2006
    ..In 130 hospitalized patients who were administered amikacin, gentamicin, tobramycin, and vancomycin by intermittent intravenous infusion, we compared the predicted GFR ..
  76. ncbi Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma
    Lorena Baietto
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera 164, Turin 10149, Italy
    Anal Bioanal Chem 396:791-8. 2010
    A simultaneous extraction method to measure daptomycin, amikacin, gentamicin, and rifampicin in human plasma, by high-performance liquid chromatography, was developed and validated...
  77. ncbi Protective effect of aminoguanidine against nephrotoxicity induced by amikacin in rats
    H Parlakpinar
    Department of Pharmacology, Faculty of Medicine, Inonu University, 44069, Malatya, Turkey
    Urol Res 32:278-82. 2004
    ..We investigated the effects of AG on amikacin (AK)-induced changes of renal malondialdehyde (MDA), glutathione (GSH), blood urea nitrogen (BUN), serum ..
  78. ncbi Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models
    J M Labaune
    Department of Neonatology, Debrousse Hospital, Cl. Bernard University, Lyon, France
    Biol Neonate 80:142-7. 2001
    b>Amikacin is widely used in the treatment of suspected or confirmed neonatal infections. However, dosage regimens are not well defined in this group of patients because of a wide inter-individual pharmacokinetic variability...
  79. ncbi Vascular prostheses with covalently bound gentamicin and amikacin reveal superior antibacterial properties than silver-impregnated ones--an in vitro study
    M Osińska-Jaroszuk
    Department of Biochemistry, M Curie Skłodowska University, Lublin, Poland
    Eur J Vasc Endovasc Surg 38:697-706. 2009
    ..This study aims to compare the antibacterial activities of vascular prostheses: silver-impregnated and modified with covalently immobilised antibiotics...
  80. ncbi Monitoring the mode of action of antibiotics using Raman spectroscopy: investigating subinhibitory effects of amikacin on Pseudomonas aeruginosa
    E Consuelo López-Díez
    School of Chemistry, The University of Manchester, P O Box 88, Sackville Street, Manchester, M60 1QD, United Kingdom
    Anal Chem 77:2901-6. 2005
    ..The clustering pattern in the discriminant factors space correlated directly to the concentration of amikacin, and partial least squares (PLS) regression analysis of the UVRR spectra was able to predict the concentration of ..
  81. ncbi Amikacin alters auditory brainstem conduction time in newborns
    Adrian Poblano
    Department of Neurology, National Institute of Perinatology, Department of Neurological Rehabilitation, Metropolitan University at Xochimilco, Mexico
    J Perinat Med 31:237-41. 2003
    The purpose of this paper was to describe whether there are some relationships between amikacin serum levels and central conduction time in brainstem auditory evoked potentials (BAEP) within therapeutic range levels in newborns as index ..
  82. ncbi Protective effects of caffeic acid phenethyl ester (CAPE) on amikacin-induced nephrotoxicity in rats
    Hakan Parlakpinar
    Department of Pharmacology, Faculty of Medicine, Inonu University, Malatya, Turkey
    Cell Biochem Funct 24:363-7. 2006
    b>Amikacin (AK) has nephrotoxic side effects. AK-induced nephrotoxicity may be the consequence of oxidative stress and so anti-oxidant agents could be useful in reducing AK toxicity...
  83. ncbi Fin reduction is a novel and unexpected teratogenic effect of amikacin-treated zebrafish embryos
    Ying Hsin Chen
    Institute of Medical Sciences, Buddhist Tzu Chi University, Hualien, Taiwan
    Toxicol Mech Methods 22:151-8. 2012
    We used zebrafish as a model to assess amikacin-induced embryotoxicity. We exposed zebrafish embryos to amikacin, using different amikacin doses (0-10 ppm), durations (12-48 h), and onsets (0, 24, 48 hpf)...
  84. ncbi Pharmacokinetics and pharmacodynamics of enrofloxacin and a low dose of amikacin administered via regional intravenous limb perfusion in standing horses
    Alberto Parra-Sanchez
    Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
    Am J Vet Res 67:1687-95. 2006
    To evaluate the pharmacokinetic-pharmacodynamic parameters of enrofloxacin and a low dose of amikacin administered via regional IV limb perfusion (RILP) in standing horses.
  85. ncbi Dissemination of 16S rRNA methylase-mediated highly amikacin-resistant isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea
    Hyukmin Lee
    Department of Laboratory Medicine, Kwandong University College of Medicine, Kyunggido 412 270, South Korea
    Diagn Microbiol Infect Dis 56:305-12. 2006
    Novel 16S rRNA methylase-mediated high-level resistance to amikacin and arbekacin has been reported recently in clinical isolates of Gram-negative bacilli only from several countries...
  86. ncbi Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients
    María Del Mar Fernández de Gatta
    Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Spain
    J Pharm Pharmacol 61:759-66. 2009
    The aim of this study was to evaluate the reliability for dosage individualization and Bayesian adaptive control of several literature-retrieved amikacin population pharmacokinetic models in patients who were critically ill.
  87. ncbi In vitro elution of amikacin and ticarcillin from a resorbable, self-setting, fiber reinforced calcium phosphate cement
    Ashlee E Watts
    Comparative Orthopaedics Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Vet Surg 40:563-70. 2011
    To determine in vitro elution characteristics of amikacin and ticarcillin from fiber reinforced calcium phosphate beads (FRCP).
  88. ncbi Increasing the selectivity of amikacin in rat peritoneal macrophages using carrier erythrocytes
    Elsa Briones
    Department of Pharmacy, Faculty of Pharmacy, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain
    Eur J Pharm Sci 38:320-4. 2009
    The selectivity of amikacin in macrophages in vitro and its biodistribution in peritoneal macrophages and other tissues were studied in rats using carrier erythrocytes...
  89. ncbi Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model
    Zhe Yuan
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, Texas, USA
    J Infect Dis 201:889-97. 2010
    ..Here, we report a quantitative method to assess combined killing of antimicrobial agents against 2 multidrug-resistant bacteria...
  90. ncbi Solvent-free biodegradable scleral plugs providing sustained release of vancomycin, amikacin, and dexamethasone--an in vivo study
    Yi Jie Peng
    Graduate Institute of Clinical Medical Sciences, Chang Gung University, Tao Yuan, Taiwan
    J Biomed Mater Res A 94:426-32. 2010
    ..To manufacture plugs, poly(lactide-glycolide) copolymers were first mixed with vancomycin, amikacin, and dexamethasone. The mixture was compressed and sintered at 55 degrees C to form scleral plugs 1...
  91. ncbi Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis
    Mitra Ranjbar
    Department of Infectious Diseases, Sina Hospital, Hamedan, Iran
    Int J Infect Dis 11:152-6. 2007
    ..In this study we compare the standard regimen of the WHO, doxycycline-rifampin (DR), to triple therapy with doxycycline-rifampin-amikacin (ADR).
  92. ncbi Influence of subinhibitory concentrations of amikacin and ciprofloxacin on morphology and adherence ability of uropathogenic strains
    D Wojnicz
    Department of Biology and Medical Parasitology, Medical University of Wrocław, 50 367 Wrocław, Poland
    Folia Microbiol (Praha) 52:429-36. 2007
    The influence of subinhibitory concentrations (1/2, 1/4, 1/8, 1/16 and 1/32 MIC) of amikacin and ciprofloxacin on the morphology and adherence of uropathogenic strains was studied...
  93. ncbi Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study
    Miguel A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain
    Curr Med Res Opin 21:645-55. 2005
    ..However, it is not clear whether such combinations are advantageous over therapy with a broad-spectrum antibiotic...
  94. ncbi Nocardia keratitis: a case report
    S Matuska
    Department of Ophthalmology and Visual Sciences, University Hospital San Raffaele, Milano, Italy
    Eur J Ophthalmol 16:164-7. 2006
    To describe a case of Nocardia keratitis resistant to 2% amikacin, with a toxic-allergic reaction to fortified topical 5% amikacin, and recurrence of the infection with topical corticosteroids.
  95. ncbi Real-time PCR for single-nucleotide polymorphism detection in the 16S rRNA gene as an indicator for extensive drug resistance in Mycobacterium tuberculosis
    Marion Blaschitz
    Austrian Agency for Health and Food Safety, Institute for Medical Microbiology and Hygiene, Währingerstrasse 25a, 1090 Vienna, Austria
    J Antimicrob Chemother 66:1243-6. 2011
    ..at positions 1401, 1402 and 1484 of the 16S rRNA gene of Mycobacterium tuberculosis leading to resistance to amikacin, kanamycin and capreomycin...
  96. ncbi Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains
    C Bantar
    Department of Microbiology, Centro de Educación Médica e Investigaciones Clínicas Dr Norberto Quirno, Billingurst 2447, 1425, Buenos Aires, Argentina
    Diagn Microbiol Infect Dis 37:41-4. 2000
    ..bactericidal activity of cefepime (CFP) and ceftazidime (CZD) (at 4 and 16 microg/mL), alone and associated with amikacin (AMK) (4 microg/mL). CFP proved more active than CZD (p < 0.05, Student's t test)...
  97. ncbi Long-lasting potentiation of a single-dose of rocuronium by amikacin: case report
    V Gilliard
    Service d anesthésiologie, Cliniques Universitaires de Mont Godinne, Avenue G Therasse, 1, B 5530 Yvoir, Belgium
    Acta Anaesthesiol Belg 57:157-9. 2006
    ..to our knowledge long-lasting (4 hours) potentiation of single intubating dose of rocuronium by a single bolus of amikacin given 55 minutes later in a woman having no precipitating factor (renal failure, hepatic failure, ionic disorder, ..
  98. ncbi Calpain activity in the amikacin-damaged rat cochlea
    Sabine Ladrech
    Institut National de la Santé et de la Recherche Médicale U583 et Université Montpellier I, Laboratoire de Physiopathologie et thérapie des déficits sensoriels et moteurs, 34295 Montpellier, France
    J Comp Neurol 477:149-60. 2004
    ..study was to investigate the involvement of calpain in the degeneration of hair cells and ganglion neurons in the amikacin-poisoned rat cochlea...
  99. ncbi Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin
    I Sugawara
    Mycobacterial Reference Center, The Research Institute of Tuberculosis, 3 1 24 Matsuyama, Kiyose, Tokyo 204 0022, Japan
    Indian J Exp Biol 47:520-2. 2009
    ..isolates were subjected to cross-resistance drug testing against two major aminoglycosides, kanamycin (KM) and amikacin (AMK). Among them, 15 clinical isolates (20.3%) were resistant to both KM and AMK...
  100. ncbi Changes in MAP2 and tyrosinated alpha-tubulin expression in cochlear inner hair cells after amikacin treatment in the rat
    Sabine Ladrech
    INSERM U254, Universite Montpellier I, Faculte de Medecine, Montpellier, France
    J Comp Neurol 451:70-8. 2002
    ..protein 2) and of tyrosinated alpha-tubulin was investigated immunocytochemically in the cochleas of normal and amikacin-treated rats...
  101. ncbi Development and optimization of solid lipid nanoparticles of amikacin by central composite design
    Jaleh Varshosaz
    Department of Pharmaceutics, Isfahan University of Medical Sciences, Iran
    J Liposome Res 20:97-104. 2010
    ..fractional factorial design was applied to examine which variables affect the physicochemical properties of amikacin SLNs...

Research Grants21

  1. Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis
    Michelle M Butler; Fiscal Year: 2013
    ..e., amikacin, kanamycin, or capreomycin)]...
  2. Aminoglycoside potentiators for P. aeruginosa therapy
    Donald T Moir; Fiscal Year: 2013
    ..exhibits an alarming variety of intrinsic drug resistances, aminoglycosides (AMGs) such as tobramycin and amikacin, are still effective in treating diseases caused by this pathogen, including CF and ventilator- associated ..
  3. In vitro and in vivo efficacy of liposomal ciprofloxacin formulations against Myc
    Igor Gonda; Fiscal Year: 2013
    ..of CFI and DRCFI in the macrophage test system: a) alone and in combination with clarithromycin, ethambutol, and amikacin against 3 clinical isolates of M...
  4. Firing up new treatments against Mycobacterium ulcerans disease (Buruli ulcer)
    Jacques H Grosset; Fiscal Year: 2013
    ..ulcerans disease and demonstrated that treatment for two months with amikacin (or streptomycin) and rifampin, used in the mouse at doses equipotent to human doses, was highly active (..
  5. Mechanistic Basis Underlying Protein Repair of CFTR Nonsense Mutations
    STEVEN MARK ROWE; Fiscal Year: 2010
    ..While initial studies with gentamicin, amikacin, and the novel small molecule PTC124 indicate significant promise to the approach, successfully employing the ..
  6. Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis
    Antonino Catanzaro; Fiscal Year: 2013
    ..e., isoniazid, rifampin, ofloxacin, amikacin, kanamycin, and capreomycin) directly from sputa...
  7. Multidrug-Resistant Acinetobacter baumannii
    Yohei Doi; Fiscal Year: 2010
    ..In Pittsburgh, there is a surge in imipenem-resistant and amikacin-resistant A. baumannii, necessitating use of salvage agents such as colistin and tigecycline...
  8. PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDREN
    ANNEKE CATHARINA HESSELING; Fiscal Year: 2013
    ..frequently used second-line anti-TB drugs in children in the PIs'setting are ethionamide, fluoroquinolones, amikacin and terizidone. Capreomycin, linezolid and PAS are typically used for treatment of extensively drug-resistant TB...
  9. Nanoparticle delivery system for antiturberculosis drug
    Leonid Heifets; Fiscal Year: 2004
    ..5-7 fold. Dr. Geuelperina at RDCMDT has already begun encapsulation of ethambutol, pyrazinamide, capreomycin, amikacin, kanamycin, ethionamide, levofloxacin, cycloserine, moxifloxacin, vancomycin, and cefoxitin...
  10. Dealing with Antibiotic Resistance: Antisense Technology
    Marcelo E Tolmasky; Fiscal Year: 2013
    ..the most clinically relevant acetyltransferase among gram-negative pathogens, which mediates resistance to amikacin (Ak) and other aminoglycosides...
  11. NEW DRUGS FOR RESISTANT DISEASE FROM CI/MS STUDIES
    VERONICA BIERBAUM; Fiscal Year: 2000
    ..The aminoglycoside antibiotics such as gentamycin, tobramycin, neomycin, and amikacin will also be examined in conjunction with resistant and sensitive strains of E...
  12. ACTIVE-SITE CHARACTERIZATION FOR APH(3')-II
    Michael Perlin; Fiscal Year: 1992
    ..This enzyme normally confers bacterial resistance to kanamycin, but not to its semi-synthetic derivative, amikacin. This is true even though the enzyme modifies amikacin, albeit with much less catalytic efficiency than for ..
  13. AEROSOL DELIVERY OF DRUGS TO TB PATIENTS
    Neil Schluger; Fiscal Year: 1999
    ..Specific Aim 2: To assess the effect of aerosol amikacin on clearance of mycobacteria from the lungs of patients with pulmonary tuberculosis.
  14. Genomics in Discovering Antibiotic Resistance Mechanisms
    Michael Lynch; Fiscal Year: 2005
    ..aeruginosa that are involved in its resistance to the aminoglycoside: amikacin. Techniques utilized will include parallel gene trait mapping (PGTM), insertional mutagenesis, and a bacterial ..
  15. MODULATION OF PULMONARY RESPONSES TO PATHOGENS
    Blaine Beaman; Fiscal Year: 2001
    ..These studies will determine the importance of the structure of mycobacterial glycolipids on mechanisms regulating T cell function during pulmonary protection especially as related to AIDS. ..
  16. MECHANISMS OF HEMOSTASIS AND REPAIR IN THE LUNG
    Blaine Beaman; Fiscal Year: 2004
    ..The goal of this research is to reveal those attributes of gamma delta T cell function that contribute to epithelial integrity, and when breached determine the beneficial levels of inflammation and repair. ..
  17. Mouse Strain dependent innate resistance to intestinal amebiasis
    Eric Houpt; Fiscal Year: 2009
    ....
  18. Real-time PCR diagnostic kit for Giardia and Cryptosporidium
    Eric Houpt; Fiscal Year: 2006
    ..A Phase II application is anticipated to validate the final diagnostic test product against immunoassay for an FDA 501 (k) medical device application. [unreadable] [unreadable] [unreadable]..
  19. Mucosal immune regulation in murine amebic colitis
    Eric Houpt; Fiscal Year: 2007
    ..The comprehensive approach in training and research laid out in this research proposal will guide the applicant towards his goal of being an independent investigator in immunoparasitology. ..
  20. Multiplex bead-PCR diagnosis for AIDS diarrhea
    Eric Houpt; Fiscal Year: 2007
    ..Finally, syndrome-based multiplex diagnosis is the platform of the future for clinical microbiology, and if this assay works on stool it should work on sputum, blood, or spinal fluid. [unreadable] [unreadable] [unreadable]..
  21. Targeted DNA extraction for Tuberculosis PCR from sputum
    Eric Houpt; Fiscal Year: 2007
    ..The most sensitive procedure will be taken in Phase II and adapted to high-throughput DNA extraction platforms and compared against the standard E- MTD assay. [unreadable] [unreadable] [unreadable]..